Clinical Trials Logo

Biliary Tract Cancer (BTC) clinical trials

View clinical trials related to Biliary Tract Cancer (BTC).

Filter by:
  • None
  • Page 1

NCT ID: NCT05036486 Recruiting - Clinical trials for Biliary Tract Cancer (BTC)

The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer

Start date: October 25, 2021
Phase:
Study type: Observational [Patient Registry]

Recent progress in comprehensive genomic profiling for advanced BTC has helped to clarify tumorigenesis and facilitate the coming era of precision medicine. To further elucidate the underlying molecular genomic aberrations, as well as the clinical demographics and therapeutic outcomes, it is necessary to have a national, multi-centers and population-focused research project to collect data completely. Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis in a platform of data storage and sharing. The purpose of the precision medicine project is to establish tumor molecular profiling of BTC populations in Taiwan, to facilitate patients to have corresponding potential targeted therapeutics and suitable clinical trials.

NCT ID: NCT04004234 Recruiting - Clinical trials for Biliary Tract Cancer (BTC)

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Start date: March 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Biliary tract cancer (BTC) is a rare heterogeneous collection of malignancies arising within the biliary tract, characterized by innate chemoresistance and abysmal prognosis. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This open-label, phase I/II study is designed to assess the safety and efficacy of Manganese primed combined therapy of anti-PD-1 antibody and gemcitabine/cisplatin chemotherapy.

NCT ID: NCT03790111 Terminated - Clinical trials for Biliary Tract Cancer (BTC)

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

TELE-ABC
Start date: March 13, 2019
Phase: Phase 2
Study type: Interventional

A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem])

NCT ID: NCT03314935 Completed - Ovarian Cancer Clinical Trials

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Start date: November 21, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.